Anti-proliferative and pro-apoptotic effects of lichen-derived compound protolichesterinic acid are not mediated by its lipoxygenase-inhibitory activity. 2015

M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; Faculty of Pharmaceutical Sciences, University of Iceland, 101 Reykjavik, Iceland.

Lipoxygenases (LOXs) and their products are involved in several biological functions and have been associated with carcinogenesis. Protolichesterinic acid (PA), a lichen metabolite, inhibits 5- and 12-LOX and has anti-proliferative effects on various cancer cell lines. Here, PA was shown to inhibit proliferation of multiple myeloma cells, RPMI 8226 and U266, and pancreatic cancer cells AsPC-1. Apoptosis was induced only in multiple myeloma cells. Cell-cycle associated changes in expression and sub-cellular localization of 5- and 12-LOX were not affected by PA but increased cytoplasmic localisation was found to accompany morphological changes at later stages. Assessment by mass spectrometry showed that PA entered the pancreatic cancer cells. However, effects on LOX metabolites were only evident after treatment with concentrations exceeding those having anti-proliferative effects and no effects were measurable in the myeloma cells. We conclude that the anti-proliferative and pro-apoptotic effects of PA are not mediated directly through inhibition of LOX activity.

UI MeSH Term Description Entries
D008011 Lichens Any of a group of plants formed by a symbiotic combination of a fungus with an algae or CYANOBACTERIA, and sometimes both. The fungal component makes up the bulk of the lichen and forms the basis for its name. Lichen
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001092 Arachidonate 12-Lipoxygenase An enzyme that catalyzes the oxidation of arachidonic acid to yield 12-hydroperoxyarachidonate (12-HPETE) which is itself rapidly converted by a peroxidase to 12-hydroxy-5,8,10,14-eicosatetraenoate (12-HETE). The 12-hydroperoxides are preferentially formed in PLATELETS. 12-Lipoxygenase,Arachidonic Acid 12-Lipoxygenase,12 Lipoxygenase,12-Lipoxygenase, Arachidonate,12-Lipoxygenase, Arachidonic Acid,Arachidonate 12 Lipoxygenase,Arachidonic Acid 12 Lipoxygenase
D001094 Arachidonate 5-Lipoxygenase An enzyme that catalyzes the oxidation of arachidonic acid to yield 5-hydroperoxyarachidonate (5-HPETE) which is rapidly converted by a peroxidase to 5-hydroxy-6,8,11,14-eicosatetraenoate (5-HETE). The 5-hydroperoxides are preferentially formed in leukocytes. 5-Lipoxygenase,Arachidonic Acid 5-Lipoxygenase,LTA4 Synthase,Leukotriene A Synthase,Leukotriene A4 Synthase,Leukotriene A4 Synthetase,5 Lipoxygenase,5-Lipoxygenase, Arachidonate,5-Lipoxygenase, Arachidonic Acid,Arachidonate 5 Lipoxygenase,Arachidonic Acid 5 Lipoxygenase,Synthase, LTA4,Synthase, Leukotriene A,Synthase, Leukotriene A4,Synthetase, Leukotriene A4
D015107 4-Butyrolactone One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent. 1,4-Butanolide,4-Hydroxybutyric Acid Lactone,Furanone, tetrahydro-2-,gamma-Butyrolactone,Dihydro-2(3H)-furanone,1,4 Butanolide,4 Butyrolactone,4 Hydroxybutyric Acid Lactone,Furanone, tetrahydro 2,Lactone, 4-Hydroxybutyric Acid,gamma Butyrolactone
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic

Related Publications

M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
September 2022, Planta medica,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
October 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
December 2015, Journal of cellular physiology,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
April 2017, Oncotarget,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
July 2013, Current eye research,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
January 2003, Zeitschrift fur Naturforschung. C, Journal of biosciences,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
January 2021, OncoTargets and therapy,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
January 1998, The Journal of pharmacy and pharmacology,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
February 2022, Cellular and molecular life sciences : CMLS,
M Bessadóttir, and F F Eiríksson, and S Becker, and M H Ögmundsdóttir, and S Ómarsdóttir, and M Thorsteinsdóttir, and H M Ögmundsdóttir
November 2021, British journal of pharmacology,
Copied contents to your clipboard!